We are very pleased to confirm the setting up of three CLL specific Support Groups in partnership with Leukaemia Care in the following locations: Cambridge, Leicester and Nottingham - see flyer below for places and times.
If you are in the area they would like to see you.
If you would like any further information or would like to attend any of these support groups, please contact: 08088. 010444 or: email@example.com
CURE Media Group, which services over a million patients, survivors and caregivers across an industry-leading multi-channel platform devoted solely to cancer updates, research and education, will honor John C. Byrd, M.D., Brian Koffman, M.D., Christopher Dwyer and Lisa Minkove as the winners of its first annual Chronic Lymphocytic Leukemia (CLL) Heroes awards ceremony. The gala will be held on Sunday, Dec. 2, at 6 p.m. at the Hard Rock Hotel San Diego during the 60thAmerican Society of Hematology Annual Meeting and Exposition.
1.1 Venetoclax with rituximab is not recommended, within its anticipated marketing authorisation, for treating relapsed or refractory chronic lymphocytic leukaemia in adults.
Cancer 52 announced the publication of our new briefing document 'Getting a better deal for people with rare and less common cancers: the next ten years'
During our consultation process over the summer regarding what's needed for people with rare and less common cancers in the NHS ten year plan we generated views and input from more than 50 of our member charities, more than 650 patients and 14 key stakeholders.
This trial is comparing ibrutinib alongside rituximab with fludarabine, cyclophosphamide, rituximab and venetoclax for chronic lymphocytic leukaemia. This trial is for people who haven’t yet had treatment for their chronic lymphocytic leukaemia (CLL). The CLLSA supports this research.
The Flair Trial researchers think that ibrutinib with rituximab, or venetoclax, might work well for people with CLL who haven’t yet had treatment. To find this out they want to compare:
fludarabine, cyclophosphamide and rituximab (FCR)
People across the UK living with the most common form of adult leukaemia are celebrating today following NHS England's decision to remove the arbitrary clause on funding the treatment Ibrutinib following months of campaigning by the blood cancer community.